8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Oct 23, 2018)

Filed October 23, 2018For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on October 23, 2018, primarily to furnish a press release detailing its third-quarter 2018 results. While the filing itself does not contain extensive new details, it points investors to the press release for comprehensive information regarding the company's operational and financial performance for the quarter ended September 30, 2018. Investors should review the furnished press release for specific financial metrics, revenue figures, and any forward-looking statements or strategic updates provided by management during that period. This filing serves as an official notification of the release of quarterly earnings. The key takeaway for investors is to access the attached press release (Exhibit 99.1) to understand Biogen's performance, including any changes in key product revenues, pipeline updates, or financial guidance that would impact their investment decisions. The disclaimer language indicates that the information is furnished and not formally 'filed' for certain legal purposes, which is standard for such press release disclosures.

Key Highlights

  • 1Biogen Inc. announced its third-quarter 2018 financial results via a press release furnished with this 8-K filing.
  • 2The filing is dated October 23, 2018, and pertains to the quarter ended September 30, 2018.
  • 3The press release (Exhibit 99.1) contains the detailed operational and financial performance data for the quarter.
  • 4Investors are directed to the furnished press release for specific financial and operational information.
  • 5The filing includes standard disclaimers regarding the 'furnished' nature of the press release, meaning it's not deemed 'filed' for certain regulatory purposes.
  • 6This 8-K primarily serves as a notification mechanism for the release of quarterly earnings information.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide access to Biogen's press release detailing its third-quarter 2018 financial and operational results.

The specific financial results are contained within the press release dated October 23, 2018, which is furnished as Exhibit 99.1 to this 8-K filing. Investors should review this exhibit for detailed information.

This 8-K filing itself does not contain new guidance or updates; it only furnishes the press release where such information would typically be found. Investors need to consult Exhibit 99.1 for any financial guidance or strategic commentary provided by Biogen management for the third quarter of 2018.

When a press release is 'furnished' under Item 2.02, it means it's being provided to the SEC for informational purposes, but it is not considered 'filed' under Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. This is a common practice for earnings releases and is standard disclosure language.